Cargando…

Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score

BACKGROUND: Evidence guiding personalized decision-making with respect to disease-modifying therapy (DMT) around pregnancy in relapsing multiple sclerosis (RMS) is lacking. OBJECTIVE: To generate and validate a risk score for disease reactivation intrapartum and postpartum in RMS. METHODS: From the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bsteh, Gabriel, Hegen, Harald, Riedl, Katharina, Altmann, Patrick, Di Pauli, Franziska, Ehling, Rainer, Zulehner, Gudrun, Rommer, Paulus, Leutmezer, Fritz, Deisenhammer, Florian, Berger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801570/ https://www.ncbi.nlm.nih.gov/pubmed/35111123 http://dx.doi.org/10.3389/fneur.2021.766956

Ejemplares similares

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2023)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Has the pandemic changed treatment strategy in multiple sclerosis?
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
por: Krajnc, Nik, et al.
Publicado: (2022)

COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial
por: Altmann, Patrick, et al.
Publicado: (2022)

Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial
por: Altmann, Patrick, et al.
Publicado: (2022)

Smoking is not associated with higher prevalence of JC virus in MS patients
por: Auer, Michael, et al.
Publicado: (2018)

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021)

Impact of vaccination on COVID‐19 outcome in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study
por: Bsteh, Gabriel, et al.
Publicado: (2016)

Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)

The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study
por: Altmann, Patrick, et al.
Publicado: (2021)

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
por: Wurth, Sebastian, et al.
Publicado: (2017)

Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort
por: Schurz, Natascha, et al.
Publicado: (2021)

Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
por: Monschein, Tobias, et al.
Publicado: (2020)

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
por: Auer, Michael, et al.
Publicado: (2019)

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017)

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
por: Berek, Klaus, et al.
Publicado: (2021)

Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Serum neurofilament light chain withstands delayed freezing and repeated thawing
por: Altmann, Patrick, et al.
Publicado: (2020)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Altmann, Patrick, et al.
Publicado: (2022)

Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Altmann, Patrick, et al.
Publicado: (2021)

Longitudinal ventricular cerebrospinal fluid profile in patients with spontaneous subarachnoid hemorrhage
por: Zinganell, Anne, et al.
Publicado: (2022)

FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Influence of physical activity on serum vitamin D levels in people with multiple sclerosis
por: Bauer, Angelika, et al.
Publicado: (2020)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
por: Auer, Michael, et al.
Publicado: (2021)

Correction to: FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4gcr8iai9jg0dnne1op4kb7d6t